Dr. Rebecca Burdine is professor in the Department of Molecular Biology at Princeton University. Her lab focuses on understanding the mechanisms that control left-right patterning and asymmetric organ morphogenesis. She was named the 44th Mallinckrodt Scholar for the Edward Mallinckrodt Jr. Foundation, and received a Scientist Development Career Award from the American Heart Association in 2003. She was elected as fellow to the American Association for the Advancement of Science (AAAS) in 2018. She is serving on the Boards of the Genetics Society of America, The International Society of Differentiation, and the International Zebrafish Society. She is on the Editorial board for Cell Reports and Zebrafish, and regularly serves on grant review panels for the NIH and NSF. 

Dr. Burdine graduated summa cum laude from Western Kentucky University, majoring in Recombinant Gene Technology with a minor in Chemistry. She received her Ph.D. from Yale University for her thesis work with Dr. Michael Stern. Dr. Burdine carried out her postdoctoral research in the laboratory of Alexander F. Schier (Harvard) when he was at the Skirball Institute of Biomolecular Medicine at New York University. 

Dr. Burdine is a parent to a child with Angelman Syndrome. She first served on the Angelman Syndrome Foundation (ASF) scientific advisory committee in 2007 by invitation from Dr. Joe Wagstaff. She has previously served as Chief Scientific Officer for the Pitt-Hopkins Research Foundation and for the Foundation for Angelman Syndrome Therapeutics. She is currently serving on the steering committee for the Angelman Syndrome Natural History study, the Scientific Advisory Committee for the ASF, and the Board of Directors for the ASF. Dr. Burdine is serving as a patient representative on the Clinical Trial Steering Committee for the STARS and NEPTUNE studies conducted by Ovid Therapeutics for AS.

LinkedIn Profile